Literature DB >> 14978659

Priorities for treatment research from different professional perspectives.

William E Whitehead1, Arnold Wald, Nancy J Norton.   

Abstract

The consensus conference "Advancing the Treatment of Fecal and Urinary Incontinence Through Research" had as one of its goals the development of a comprehensive list of research priorities. Experts from all disciplines that treat incontinence-gastroenterology, pediatric gastroenterology, urology, urogynecology, colorectal surgery, geriatrics, neurology, nursing, and psychology-and patient advocates were asked to identify their highest priorities for treatment-related research. Meeting participants were shown the aggregated list and invited to propose additional priorities. Treatments for fecal incontinence (biofeedback, sphincteroplasty, antidiarrheal and laxative medications, and sacral nerve stimulation) require validation by randomized, controlled trials. For urinary incontinence, the greatest need is to compare pharmacological, behavioral, and surgical treatments. Trials assessing combined treatments (e.g., biofeedback plus surgery vs. surgery alone or biofeedback alone) are also needed. New drugs are needed that target anal canal resting pressure in fecal incontinence and hypersensitivity to distention in urge urinary incontinence. It may be possible to substantially reduce the incidence of incontinence through modification of obstetric practices (e.g., avoiding episiotomies or offering elective cesarean delivery to high-risk patients), providing pelvic floor exercises before childbirth, and educating patients to avoid straining during defecation. For the elderly, practical behavioral and pharmacological treatments are needed that can postpone or avoid institutionalization. Social science research may identify ways to counteract the social stigma of fecal incontinence and assist physicians in providing patients with more comprehensive and understandable information on the risks associated with different treatment options.

Entities:  

Mesh:

Year:  2004        PMID: 14978659     DOI: 10.1053/j.gastro.2003.10.082

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  6 in total

Review 1.  Patients' and clinicians' research priorities.

Authors:  Ruth J Stewart; Jenny Caird; Kathryn Oliver; Sandy Oliver
Journal:  Health Expect       Date:  2010-12-22       Impact factor: 3.377

2.  Rapid priority setting exercise on faecal incontinence for Cochrane Incontinence.

Authors:  Katie H Thomson; Nicole O'Connor; Kim Tuyen Dangova; Sean Gill; Sara Jackson; Donna Z Bliss; Sheila A Wallace; Fiona Pearson
Journal:  BMJ Open Gastroenterol       Date:  2022-05

3.  Randomized controlled trial shows biofeedback to be superior to pelvic floor exercises for fecal incontinence.

Authors:  Steve Heymen; Yolanda Scarlett; Kenneth Jones; Yehuda Ringel; Douglas Drossman; William E Whitehead
Journal:  Dis Colon Rectum       Date:  2009-10       Impact factor: 4.585

4.  Anatomical disruption and length-tension dysfunction of anal sphincter complex muscles in women with fecal incontinence.

Authors:  Young Sun Kim; Milena Weinstein; Varuna Raizada; Yanfen Jiang; Valmik Bhargava; M Raj Rajasekaran; Ravinder K Mittal
Journal:  Dis Colon Rectum       Date:  2013-11       Impact factor: 4.585

5.  Can the outcome of pelvic-floor rehabilitation in patients with fecal incontinence be predicted?

Authors:  M P Terra; M Deutekom; A C Dobben; C G M I Baeten; L W M Janssen; G E E Boeckxstaens; A F Engel; R J F Felt-Bersma; J F W Slors; M F Gerhards; A B Bijnen; E Everhardt; W R Schouten; B Berghmans; P M M Bossuyt; J Stoker
Journal:  Int J Colorectal Dis       Date:  2008-01-29       Impact factor: 2.571

6.  Participatory methods for research prioritization in primary care: an analysis of the World Café approach in Ireland and the USA.

Authors:  Anne MacFarlane; Rose Galvin; Madeleine O'Sullivan; Chris McInerney; Eoghan Meagher; Daniel Burke; Joseph W LeMaster
Journal:  Fam Pract       Date:  2017-06-01       Impact factor: 2.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.